| 摘要 |
The disclosure relates to salts of pyrimidinyl pyridazinone derivates, particularly disclosed are sulphate, mesylate, besylate, p-tosylate, fumarate and maleate salts of 6-(1-Methyl-1H-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-ylethoxy)-pyrimidin-2-yl]benzyl} -2H-pyridazin-3-one; and hydrochloride monohydrate, hydrobromide, mesylate, besylate, malate, p-tosylate, fumarate and maleate salts of 3-(1-{ 3-[5-(1-Methylpiperidin-4-ylmethoxy)pyrimidin-2-yl]-benzyl} -6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile. These compounds are inhibitors of tyrosine kinases, especially of Met kinase, and can be used, inter alia, for treatment of tumours, where the solid tumour originates from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and/or the lung, and also where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.
|
